ADXS — Ayala Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $24.30m
- $27.23m
- $0.01m
Immunome slides on $200 mln equity offering
Immunome edges up after $200 mln equity offering
Brief: Immunome To Acquire AL102 Phase 3 Asset for the Treatment of Desmoid Tumors From Ayala Pharmaceuticals
Brief: Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
Brief: Ayala Pharmaceuticals posts Q2 EPS USD -1.82
Brief: Ayala Pharmaceuticals And Biosight Enter Into Definitive Merger Agreement
Brief: Ayala Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA Regarding Al102 For The Treatment Of Desmoid Tumors
Brief: Ayala Pharmaceuticals Announces Continuation Of Ringside Phase 2/3 Study In Desmoid Tumors
Ayala Pharma jumps after merger deal with Advaxis
Brief: Ayala Pharmaceuticals And Advaxis Enter Into Merger Agreement
Brief: Advaxis Applies To List Common Stock On Nasdaq Under Symbol "ADXS" - SEC Filing
Brief: Advaxis Presents Updated Clinical Data From Ongoing Phase 1/2 Trial Of ADXS-503 In NSCLC And Upcoming Milestones
Brief: Advaxis To Continue To Explore Additional Options To Maximize Stockholder Value
Brief: Advaxis Issues Letter To Stockholders Regarding Recent Special Meeting Results
Brief: Advaxis Issues Letter To Stockholders Regarding Upcoming Special Meeting
Brief: Advaxis Inc Issues Letter To Stockholders
Brief: Glass Lewis & Co Joins Institutional Shareholder Services In Recommending Advaxis Stockholders Vote "For" Proposals On Proposed Merger With Biosight
Brief: Advaxis Entered Agreement With PIPE Investors For $21 Million In Co Shares
Brief: Advaxis Inc - ISS Recommends Advaxis Stockholders Vote “FOR” Merger With Biosight